Regulatory-affairs lead must resolve whether a CMO finding is a delay

Situation

A CMO finding is sits with regulatory-affairs lead because an inspector asking for batch records you cannot produce this week hit a mid-size sponsor after a complete response letter. Evidence is disproportionate reporting signal workbook; write the Pharma & Life Sciences FDA Response and Labeling option that extract can carry.

Decision

Regulatory-affairs lead in a mid-size sponsor after a complete response letter must choose A CMO finding is a delay / A refuse-to-file risk using disproportionate reporting signal workbook after an inspector asking for batch records you cannot produce this week.

Hypotheses to test

• Disproportionate reporting signal workbook reads as A CMO finding is a delay once an inspector asking for batch records you cannot produce this week is lined up to the same Pharma & Life Sciences population.
• Disproportionate reporting signal workbook is closer to A refuse-to-file risk after an inspector asking for batch records you cannot produce this week; A CMO finding is a delay would over-claim this FDA Response and Labeling extract.
• A dual reading is still live in disproportionate reporting signal workbook for regulatory-affairs lead in a mid-size sponsor after a complete response letter.
• Disproportionate reporting signal workbook is missing the fact regulatory-affairs lead needs after an inspector asking for batch records you cannot produce this week; stop this Pharma & Life Sciences close.

Analysis required

• Map FDA-response timing and owner in a mid-size sponsor after a complete response letter.
• Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after an inspector asking for batch records you cannot produce this week.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences FDA Response and Labeling file, read disproportionate reporting signal workbook against an inspector asking for batch records you cannot produce this week and write the one fact that would move a CMO finding is for regulatory-affairs lead.

Recommendation

Choose A CMO finding is a delay / A refuse-to-file risk on this Pharma & Life Sciences / FDA Response and Labeling packet (disproportionate reporting signal workbook after an inspector asking for batch records you cannot produce this week). Lead with the Pharma & Life Sciences option disproportionate reporting signal workbook can support after an inspector asking for batch records you cannot produce this week, then the two facts that force it, then the Monday action for regulatory-affairs lead in a mid-size sponsor after a complete response letter.